Presentazione standard di PowerPoint - ICE Tokyo · Assobiotec The Italian Association for the...
14
Foreign Direct Investment Department Italian Trade Agency – Rome London 20 th September 2016 Biotech Presentation by Riccardo Palmisano President of Assobiotec
Transcript of Presentazione standard di PowerPoint - ICE Tokyo · Assobiotec The Italian Association for the...
Foreign Direct Investment Department
Italian Trade Agency – Rome
London 20th September 2016
Biotech
Presentation by Riccardo Palmisano
President of Assobiotec
Assobiotec
The Italian Association for the development of biotechnology
More than 140 companies and science & technology parks
MISSION: fostering, supporting and defending the development of biotechnology in all its application fields
Biotech: a growing sector
From 2013 to 2014:
• +1,6% biotech firms
• +4,2% turnover
• +4,5% investments
The Italian biotech is growing and Italy is at the 4th place for number life science firms in Europe
A high-research intense industry
R&D employees on total employees
Intra-muros R&D investments on total turnover
Biotech R&D dedicated vs manufacturing
13 times more employees in R&D activities
14 times more investments in R&D
Biotech vs manufacturing
5 times more employees in R&D activities
2.5 times more investments in R&D
Breakdown of the biotech firms by sector and size
Biotech Red Green White
Number of firms 489 261 44 119
Turnover (*1000€) 9.440.916 7.131.284 592.906 1.642.815
Investments in R&D (*1000€) 1.855.187 455.902 8.261 33.523
Biotech employees 9.229 6.566 897 1.352
Biotech R&S employees 3.670 2.911 144 436
Red biotech: products
More than 40% of the R&D projects relates to
biopharmaceuticals: monoclonal antibodies,
recombinant proteins, vaccines and Advanced
Therapy products – half of which are still in
preclinical phase – that open a radically new
perspective for the treatment of a number
unmet medical needs and Rare Disease
Italian excellence: red biotech/pipeline
Italian companies’ investments are mainly focused on those therapeutic areas that are still associated to
a number of unmet medical needs (i.e.: oncology and immunology), or are becoming increasingly
relevant, both from an epidemiological and clinical point of view, due to the overall aging of the
population.
The WHO has selected two Italian vaccines to tackle the Ebola epidemics
Italian excellence: red biotech/advanced therapies and orphan drugs
7 companies obtained an ODD
4 in the Phase III clinical development
29 project of advanced therapies
8 projects already at the development stage
1 product recently received the marketing authorization by EMA
ADVANCED THERAPIES’ MANUFACTURING FACILITIES
Excellence of the Italian manufacturing processes is internationally recognised
Italian excellence: white biotech/biorefineries 6
FLA
GSH
IPS!
!!
Showcase stories
Defitelio® (Defibrotide), is a life-saving drug for the treatment of severe hepatic
veno-occlusive disease (VOD)
Xadago® (Safinamide), an adjunctive therapy to L-DOPA alone or in combination
with other therapies for mid to late-stage Parkinson's disease
Holoclar®, an Advanced Therapy for the treatment of patients with severe burns of
the cornea based on autologous stem cells
Strimvelis®, an Advanced Therapy for the treatment of children affected by ADA-
SCID by gene-replacement
Ocaliva®, a Therapy for the treatment of patients affected by for the treatment of
primary biliary cholangitis (PBC), before untreateble
Zalmoxis®, a cell therapy product for the treatment of haematological
malignancies has just been granted a conditional markenting authorisation and the
ODD
Profitability of the sector
THE ITALIAN BIOTECH FIRMS SIGNED AGREEMENTS OF BILLIONS FOR INVESTMENTS OF…MILLIONS
The Italian system focuses on innovation
In the last years, many measures have been introduced to support innovation. These
constitute a turning point for the sectors which are driving innovation in Italy.
Innovative Start-up & SME status
Tax credit for R&D and attraction of specialised human resources
Patent Box
Action plan for genetic improvement in agriculture
Local promotion to attract investments in the less developed areas
Funding to promote business creation in the Life Sciences sector: Venture
Capital and Business Angels (Italian Angels for Biotech, IAB)
and soon the HUMAN TECHNOPOLE will be build in the area of the EXPO.
Next spring don’t miss…
Thank you for the attention
Riccardo Palmisano Inserire contatti relatore Altre info
Italian Trade Commission Trade Promotion Section of the Italian Embassy Sackville House, 40 Piccadilly London W1J 0DR tel. +44 0 2072923910 [email protected] [email protected] Italian Trade Agency Via Liszt, 21 00144 Roma tel. +39 0659926607 [email protected] www.ice.gov.it
